1323199-72-9

Basic information

• Product Name: (E)-4-Morpholinobut-2-enoic acid
• Synonyms: (E)-4-Morpholinobut-2-enoic acid
• CAS NO: 1323199-72-9
• Molecular Formula: C8H13NO3
• Molecular Weight: 171.19372
• Mol File: 1323199-72-9.mol

Chemical Properties

• Boiling Point: 338.9±32.0 °C(Predicted)
• Appearance: /
• Density: 1.161±0.06 g/cm3 (20 ºC 760 Torr)
• PKA: 3.93±0.10(Predicted)
• CAS DataBase Reference: (E)-4-Morpholinobut-2-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-Morpholinobut-2-enoic acid(1323199-72-9)
• EPA Substance Registry System: (E)-4-Morpholinobut-2-enoic acid(1323199-72-9)

Safety Data

• Hazardous Substances Data: 1323199-72-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(E)-4-Morpholinobut-2-enoic acid is used as a key intermediate for the synthesis of various pharmaceuticals, given its unique chemical structure and reactivity. It plays a significant role in the development of drugs aimed at treating a wide array of medical conditions.
Used in Organic Synthesis:
In the field of organic chemistry, (E)-4-Morpholinobut-2-enoic acid is employed as a versatile building block for the creation of other complex organic compounds. Its morpholine and carboxylic acid functionalities make it a valuable component in the synthesis of various molecules with potential applications in different industries.
Used in Drug Development:
(E)-4-Morpholinobut-2-enoic acid is utilized as a crucial component in the development of new drugs for the treatment of various medical conditions. Its unique properties and reactivity contribute to the design and synthesis of novel therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 110-91-8 morpholine 
• 13991-36-1 4-bromocrotonic acid 

Relevant articles and documents

CDK KINASE INHIBITOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATION

Disclosed in the present invention are a CDK kinase inhibitor, a preparation method therefor, a pharmaceutical composition, and an application. The present invention provides a compound as represented by formula I-a, a cis-trans isomer thereof, a pharmaceutically acceptable salt thereof, a solvate of the pharmaceutically acceptable salt thereof, a tautomer thereof, or a polymorph thereof. The compound of the present invention has good CDK7 inhibitory activity, cell activity, and tumor growth inhibitory activity.

FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.

FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF

Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.

BTK INHIBITOR

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.